Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists may leads to higher bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Bleeding ‐ clinically indicated non‐major Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with heparin (moderate certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (high certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ clinically relevant, non‐major Treatment duration 28 ‐ 42… compared with heparin (high certainty).
1 finding from 1 review
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with heparin (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin leads to higher bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Time to complete healing · participants with corneal abrasion
Patching showed no clear difference in days to complete healing compared with no patching (moderate certainty).
1 finding from 1 review
Mortality in hospital or up to 30 days · people undergoing abdominal aortic surgery
Epidural pain relief showed no clear difference in mortality in hospital or up to 30 days compared with systemic opioid‐based pain relief (low certainty).
1 finding from 1 review
Pain (VAS scores) on movement at postoperative day 1 Scale from: 0 to 10. · people undergoing abdominal aortic surgery
1 finding from 1 review
Intervention not reported
Weight gain in first 7 days of study (g/day) · Newborn infants unable to fully breastfeed
1 finding from 1 review
no estimate extracted
522 participants
Low